Ð 3 M) also elicited dose-dependent inhibitions of the fMLP-induced superoxide anion production. In contrast, IL-10 (1 or 10 ng/ml) did not elicit a reduction in fMLP-induced superoxide anion production in both conditions. Principal conclusion: These results suggest that the inhibitory activity of PDE4 inhibitors on fMLPinduced production of superoxide anion production is mediated by db-cAMP rather than IL-10.
Introduction
Increased intracellular levels of the nucleotide cyclic 39 ,59 -adenosine monophosphate (cyclic AMP) and the subsequent activation of cyclic AMP-dependent protein kinase (PKA) in both the respiratory smooth muscle and inflammatory cells result in bronchodilation, reduction of inflammation and immunomodulatory activities. 1 The intracellular concentration of cyclic nucleotides is mainly determined by the activation of adenylyl cyclase coupled with adrenoceptor and G-protein, and by the breakdown of cyclic nucleotide by phosphodiesterases (PDEs). PDEs are a family of enzymes that hydrolyze the 39 -ribose phosphate bond of the naturally occurring second messenger nucleotide 39 ,59 -cyclic monophosphate to form biologically inert 59 -nucleotide monophosphate. PDEs are, at present, divided into at least seven families, each with distinct substrate specificities and regulatory characteristics. 1 Among these families, PDE3 and PDE4 are responsible for cAMP hydrolysis; however, PDE4 is mainly present in the inflammatory cells. Therefore, selective type 4 phosphodiesterase inhibitors are able to elicit an increase in intracellular cAMP content. Due to their potent anti-inflammatory activity, the interest in selective PDE4 inhibitors in the treatment of pulmonary inflammatory disorders has been greatly increasing for the past few years (for reviews, see References 2 and 3).
We previously demonstrated that PDE4 inhibitors are able to reduce the fMLP-induced arachidonate release from human mononuclear cells. 4 Nevertheless, this release was not associated with an increase in cyclic AMP in human mononuclear cells. 4 Moreover, PKA inhibitors did not reduce the inhibitory activity of selective PDE4 inhibitors on arachidonate and tumor necrosis factor-alpha (TNF-a ) release from monocytes, 5, 6 suggesting that other mechanisms are involved in the anti-inflammatory activity of selective PDE4 inhibitors. Hence, the effect of PDE4 inhibitors appeared to be partly mediated through the release of the anti-inflammatory cytokine, interleukin 10 (IL-10), 7, 8 which controls the formation of pro-inflammatory cytokine such as TNF-a .
The aim of this study was to compare the effects of two selective PDE4 inhibitors (rolipram and RP 73-401) with the cell-permeable analog of cyclic AMP, dibutyryl-cyclic AMP (db-cAMP) and IL-10 on fMLP-induced chemiluminescence in peripheral blood mononuclear cells (PBMC) preincubated in lipopolysaccharide (LPS) as a model of cellular hyperreactivity.
Materials and methods

Preparation of PBMC
Mononuclear cells were isolated from buffy coats (CRTS Rennes, France) obtained from healthy donors by density gradient centrifugation (20 min at 1100 ´g)
on Ficoll-Hypaque. Cells recovered at the interface were washed twice with phosphate-buffered saline without Ca 2+ and Mg 2+ (PBS). Mononuclear cells were resuspended in RPMI 1640 supplemented with L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 g/ml), and 10% heat-inactivated fetal calf serum (RPMI-FCS). The cells were counted and assessed for viability by Trypan blue exclusion. Under these conditions, the viability of cells exceeded 95%.
Protocol and drug treatments
Cell concentration was adjusted to 10 6 cells/ml in RPMI containing streptomycin (10 UI/ml), glutamin (2 m mol/ml) and penicillin (10 m g/ml). The cell suspensions were then placed at 4°C for 2 h. After this period, the cells were incubated with LPS (10 m g/ml) or vehicle, for 30 min at 37°C.
Then For each set of experiments, n represents the number of subjects. For each subject, the experiments using cells treated or not with LPS were carried out in triplicate.
Superoxide anion production
Immediately after the compound or vehicle treatments, peaks of maximum luminol-dependent chemiluminescence technique (LDCL) (expressed in relative light units (RLU)) after fMLP stimulation (10 -6 M) were measured on a Beckman counter on 200 000 cells in the presence of 700 m l of a luminol solution (0.02 mg/ml) (modified from Reference 9).
For kinetic study, cells were only incubated with LPS or vehicle and RLU were measured every 30 sec, 1.5 min before and 3.5 min after FMLP stimulation, using repeated measures on the same set of experiments of different subjects.
Statistical analysis
All results are expressed as means ± SEM. Statistical differences were assessed using the analysis of variance and Student's t-test. P < 0.05 was accepted as being significant. For the kinetic study, the curves were compared using two-way analysis of variance.
Drugs and chemicals
The following drugs were used: Ficoll-Hypaque (Pharmacia, Upsala, Sweden), PBS, RPMI 1640, glutamine, penicillin and streptomycin (Gibco, Cergy-Pontoise, 
Results
Time-course of the fMLP-induced LDCL
As shown in Figure 1 , there is no change in the LDCL between LPS-treated or control cells before the stimulation with fMLP. After 1.5 min of stable basal level in LDCL, the cells were stimulated with 1 m M of fMLP and a marked increase in the production of RLU was noted. However, after incubation of the cells with LPS, a large increase in LDCL was observed in comparison with control (non-treated cells) (Fig. 1) . The maximum LDCL was observed at 3 min after the beginning of the experiment, i.e. 1.5 min after the stimulation with fMLP, whether or not the cells were treated with LPS. Addition of superoxide dismutase (100 or 300 IU) to fMLP-stimulated cells induced a 50 and 90% LDCL decrease, respectively, whether or not the cells were treated with LPS (data not shown). This result demonstrates that most reactive oxygen species released from cells and measured by LDCL are superoxide anions. After stimulation of the cells with LPS, the superoxide anion production induced by fMLP was markedly enhanced. In this condition, rolipram and RP 73-401 also elicited reduction of superoxide anion production (Fig. 2) . These inhibitory effects were significant from 10 -7 M rolipram and 10 -8 M RP 73-401, and maximal inhibitions were observed at these concentrations.
Effects of db-cAMP on superoxide anion production from PBMC When the cells were incubated with db-cAMP, a dosedependent inhibition of the fMLP-induced superoxide anion production was also observed (Fig. 3 ). This inhibitory effect was similar whether the cells were incubated or not with LPS, since the effect appeared significantly from 10 -4 M db-cAMP.
Effects of IL-10 on superoxide anion production from PBMC
Incubation of PBMC with IL-10 (1 or 10 ng/ml) for 30 min did not elicit a reduction in fMLP-induced superoxide anion production, whether or not the cells were treated with LPS (Fig. 4) .
Discussion
The major finding of this study was that the selective PDE4 inhibitors rolipram and RP 73-401, as well as the PKA activator db-cAMP, but not IL-10, were able to reduce the much enhanced superoxide anion production of PBMC primed with LPS and thus stimulated with fMLP.
In the present study, we presented an in vitro model of enhanced reactivity of the human PBMC following incubation with LPS. This enhanced response is observed using the chemiluminescence technique that is mainly stimulated by superoxide production under the stimulation of the cells with fMLP.
Lipopolysaccharides are potent and pleiotropic stimuli for cells of the immune system. Stimulation of leucocytes by LPS leads to the release of cytokines and inflammatory mediators that enhance host defense against microorganisms. 10 Priming is considered to result from exposure to a low concentration of an agent, which itself has little or no effect on function but that allows a second agent to provoke a response that is larger than the non-primed response.
11 Such a priming has been previously observed for the release of 5-lipoxygenase metabolites from PBMC. 12 The mechanism of LPS-dependent priming is not completely understood. However, it has been reported that TNF-a released from monocytes stimulated with endotoxin is a potent primer of oxidative activity. 13 Regarding the superoxide anion produc- tion, it was proposed that LPS priming process represents cellular and/or biochemical alterations that increase the efficiency of NADPH oxidase assembly and the subsequent generation of superoxide anion.
14 Selective PDE4 inhibitors have been largely demonstrated to possess in vitro and in vivo anti-inflammatory activity. 2, 3, 15 For this, they also demonstrated the inhibition of the release of cytokines and arachidonic acid metabolites from resident or recruited inflammatory cells in airways. 15 Moreover, these compounds are able to diminish the reactive oxygen species from various cell types such as eosinophil, 16 -18 neutrophil, 19, 20 and peritoneal macrophages. 21 In the present study, we observed a dose-dependent inhibition by rolipram and RP 73-401 on fMLPinduced superoxide anion production in the absence or presence of pretreatment of cells with LPS. is consistent with the study of Souness et al., 22 showing that rolipram was approximately 2600-fold less potent than RP 73-401 against pig aortic smooth muscle PDE4 and about 25 times less potent against eosinophil PDE4. Interestingly, the inhibitory effects of RP 73-401 for the reduction of fMLP-induced chemiluminescence is similar to that which has been observed for the inhibition of fMLP-induced arachidonate release from mononuclear cells. 23 In this latter study, we also proposed that the PDE4 isoenzyme inhibition represents the main mechanism, leading to the arachidonate release from mononuclear cells, in contrast to the reduction of TNF-a release. Such a mechanism of action has been previously reported for the inhibition of superoxide anion production by guinea-pig eosinophils. 24 Moreover, the IC 50 of the RP 73-401 for the inhibition of LPS-induced TNF-a release is also markedly lower (0.7 nM). 23 The mechanism by which RP 73-401 presents a more potent anti-inflammatory activity when the cells are stimulated with LPS is presently unknown. One possible explanation is that additional mechanisms may be required instead of the sole inhibition of PDE4 isoenzyme and the increase in intracellular cyclic AMP.
We therefore analyzed the effects of a cell-permeable analog of cyclic AMP, db-cAMP. In our hands, dbcAMP was able to dose-dependently inhibit the fMLP- induced superoxide anion production, whether or not the cells were incubated with LPS. We have previously demonstrated that the inhibition of arachidonate release from human mononuclear cells by selective PDE4 inhibitors is not associated with a significant increase in intracellular cyclic AMP. 4 Furthermore, the fact that incubation of the cells with cyclic AMP-dependent protein kinase (PKA) inhibitors does not elicit a reduction of the in vitro antiinflammatory activities of selective PDE4 inhibitors 5, 6 suggested that other mechanisms than intracellular cyclic-AMP enhancement and PKA activation must be considered. Interestingly, Kambayashi et al. 7 have reported that rolipram can induce IL-10 release, and that IL-10 is responsible for some inhibition of TNF-a release. In our hands, IL-10 did not elicit significant inhibition of fMLP-induced production of superoxide anion whether or not the cells were treated with fMLP. This result is consistent with the study of Bussolati et al. 25 demonstrating that IL-10 did not reduce the early superoxide anion production by monocyte or polymorphonuclear neutrophils challenged with LPS, but was also able to enhance their synthesis. These results suggest that the inhibitory activity of PDE4 inhibitors on fMLP-induced production of superoxide anion production is mediated by db-cAMP rather than IL-10. In contrast, the inhibitory activity of PDE4 inhibitors on TNF-a release and neutrophilia in rats treated with LPS may be mediated by IL-10 rather than by cyclic-AMP. 
Conclusion
In conclusion, we report that incubation with LPS elicits a priming effect on the fMLP-induced superoxide anion production. Furthermore, the selective PDE4 inhibitors, rolipram and RP 73-401, as well as the cell permeable analog of cyclic-AMP (db-cAMP), but not IL-10, markedly reduced the fMLP-induced superoxide anion production in the presence or absence of the incubation of the cells with LPS. These results suggest that the inhibitory activity of PDE4 inhibitors on fMLP-induced production of superoxide anion production is mediated by db-cAMP rather than IL-10.
